![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 10, 2018 10:06:07 AM
In the long term, we forecast a growing multi-source royalty stream for OXB that will contribute alongside bioprocessing (manufacturing) revenue to its growing top line.
Due to the complexities of delivering gene therapies on this scale, we forecast that OXB is likely to receive a higher royalty rate than it receives from products that need smaller vector quantities, eg Kymriah in pALL or DLBCL.
We forecast that OXB sells vector batches to Bioverativ for $1.5m a batch, with peak gross margins of 30%.
We assume a larger than usual royalty rate of 7%. We believe OXB will likely have to incorporate an array of next-generation technology like TRiP to be able to reach the required manufacturing yields for these large indications, in turn driving increased royalties.
We forecast that OXB sells vector batches to Orchard for $1.5m a batch, with peak gross margins of 30% We assume a peak royalty rate of 2%
We forecast that OXB sells vector batches to Immune Design for $1.5m a batch, with peak gross margins of 30%. 2% royalty
http://www.edisoninvestmentresearch.com/research/report/oxford-biomedica73735/full
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM